Stevanato Gr (NYSE:STVN) is preparing to release its quarterly earnings on Wednesday, 2026-03-04. Here's a brief overview of what investors should keep in mind before the announcement.

Analysts expect Stevanato Gr to report an earnings per share (EPS) of $0.20.

The market awaits Stevanato Gr's announcement, with hopes high for news of surpassing estimates and providing upbeat guidance for the next quarter.

It's important for new investors to understand that guidance can be a significant driver of stock prices.

Past Earnings Performance

The company's EPS beat by $0.02 in the last quarter, leading to a 1.27% drop in the share price on the following day.

Here's a look at Stevanato Gr's past performance and the resulting price change:

Performance of Stevanato Gr Shares

Shares of Stevanato Gr were trading at $15.09 as of March 02. Over the last 52-week period, shares are down 23.66%. Given that these returns are generally negative, long-term shareholders are likely upset going into this earnings release.

About Stevanato Gr

Stevanato Group SpA is a provider of drug containment, drug delivery and diagnostic solutions to the pharmaceutical, biotechnology and life sciences industries. It delivers an integrated, end-to-end portfolio of products, processes, and services that address customer needs across the entire drug life cycle including development, clinical, and commercial stages. It has two segments; Biopharmaceutical and Diagnostic Solutions which generates key revenue, includes all the products, processes and services developed and provided for the containment and delivery of pharmaceutical and biotechnology drugs and reagents, as well as the production of diagnostic consumables and its other segment is Engineering. Geographically, the company derives majority revenue from Europe, Middle East and Africa.

Unraveling the Financial Story of Stevanato Gr

Market Capitalization Analysis: The company's market capitalization is below the industry average, suggesting that it is relatively smaller compared to peers. This could be due to various factors, including perceived growth potential or operational scale.

Revenue Growth: Stevanato Gr's remarkable performance in 3 months is evident. As of 30 September, 2025, the company achieved an impressive revenue growth rate of 9.11%. This signifies a substantial increase in the company's top-line earnings. As compared to its peers, the company achieved a growth rate higher than the average among peers in Health Care sector.

Net Margin: The company's net margin is a standout performer, exceeding industry averages. With an impressive net margin of 11.9%, the company showcases strong profitability and effective cost control.

Return on Equity (ROE): Stevanato Gr's ROE is below industry averages, indicating potential challenges in efficiently utilizing equity capital. With an ROE of 2.54%, the company may face hurdles in achieving optimal financial returns.

Return on Assets (ROA): The company's ROA is a standout performer, exceeding industry averages. With an impressive ROA of 1.51%, the company showcases effective utilization of assets.

Debt Management: The company maintains a balanced debt approach with a debt-to-equity ratio below industry norms, standing at 0.31.

To track all earnings releases for Stevanato Gr visit their earnings calendar on our site.

This article was generated by Benzinga's automated content engine and reviewed by an editor.